Open AccessInteraction of sildenafil and indinavir when co-administered to HIV-positive patients
Author(s) -
Concepta Merry,
Michael Barry,
Máirín Ryan,
John Tjia,
Martina Hennessy,
Victoria A. Eagling,
Fiona Mulcahy,
David Back
Publication year - 1999
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-199910220-00001
Subject(s) - indinavir , cmax , pharmacokinetics , saquinavir , ritonavir , lopinavir , sildenafil , pharmacology , medicine , dosing , drug interaction , confidence interval , nelfinavir , sida , gastroenterology , human immunodeficiency virus (hiv) , viral load , viral disease , virology , antiretroviral therapy
The prevalence of erectile dysfunction in HIV-infected men is estimated to be 33%. Sildenafil citrate (Viagra; Pfizer Ltd, Sandwich, Kent, UK) is the first oral drug for this condition. Since sildenafil and the protease inhibitors are both metabolized by, and act as inhibitors of cytochrome P450 3A4, we evaluated the pharmacokinetics of the combination sildenafil plus indinavir in HIV-infected patients.